Search

Your search keyword '"Montalban, X"' showing total 76 results
Start Over Author "Montalban, X" Journal multiple sclerosis journal
76 results on '"Montalban, X"'

1. Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study

Author

Leurs, CE, primary, Twaalfhoven, HAM, additional, Lissenberg-Witte, BI, additional, van Pesch, V, additional, Dujmovic, I, additional, Drulovic, J, additional, Castellazzi, M, additional, Bellini, T, additional, Pugliatti, M, additional, Kuhle, J, additional, Villar, LM, additional, Alvarez-Cermeño, JC, additional, Alvarez-Lafuente, R, additional, Hegen, H, additional, Deisenhammer, F, additional, Walchhofer, LM, additional, Thouvenot, E, additional, Comabella, M, additional, Montalban, X, additional, Vécsei, L, additional, Rajda, C, additional, Galimberti, D, additional, Scarpini, E, additional, Altintas, A, additional, Rejdak, K, additional, Frederiksen, JL, additional, Pihl-Jensen, G, additional, Jensen, PEH, additional, Khalil, M, additional, Voortman, MM, additional, Fazekas, F, additional, Saiz, A, additional, La Puma, D, additional, Vercammen, M, additional, Vanopdenbosch, L, additional, Uitdehaag, BMJ, additional, Killestein, J, additional, Bridel, C, additional, and Teunissen, C, additional

Published
2019
Full Text
View/download PDF

2. Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study.

Author

Leurs, CE, Twaalfhoven, HAM, Lissenberg-Witte, BI, van Pesch, V, Dujmovic, I, Drulovic, J, Castellazzi, M, Bellini, T, Pugliatti, M, Kuhle, J, Villar, LM, Alvarez-Cermeño, JC, Alvarez-Lafuente, R, Hegen, H, Deisenhammer, F, Walchhofer, LM, Thouvenot, E, Comabella, M, Montalban, X, and Vécsei, L

Subjects
GAUSSIAN mixture models, MONOCLONAL gammopathies, CEREBROSPINAL fluid, BIOMARKERS
Abstract

Objective: To validate kappa free light chain (KFLC) and lambda free light chain (LFLC) indices as a diagnostic biomarker in multiple sclerosis (MS). Methods: We performed a multicenter study including 745 patients from 18 centers (219 controls and 526 clinically isolated syndrome (CIS)/MS patients) with a known oligoclonal IgG band (OCB) status. KFLC and LFLC were measured in paired cerebrospinal fluid (CSF) and serum samples. Gaussian mixture modeling was used to define a cut-off for KFLC and LFLC indexes. Results: The cut-off for the KFLC index was 6.6 (95% confidence interval (CI) = 5.2–138.1). The cut-off for the LFLC index was 6.9 (95% CI = 4.5–22.2). For CIS/MS patients, sensitivity of the KFLC index (0.88; 95% CI = 0.85–0.90) was higher than OCB (0.82; 95%CI = 0.79–0.85; p < 0.001), but specificity (0.83; 95% CI = 0.78–0.88) was lower (OCB = 0.92; 95% CI = 0.89–0.96; p < 0.001). Both sensitivity and specificity for the LFLC index were lower than OCB. Conclusion: Compared with OCB, the KFLC index is more sensitive but less specific for diagnosing CIS/MS. Lacking an elevated KFLC index is more powerful for excluding MS compared with OCB but the latter is more important for ruling in a diagnosis of CIS/MS. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

4. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study

Author

Kuhle, J, primary, Disanto, G, additional, Dobson, R, additional, Adiutori, R, additional, Bianchi, L, additional, Topping, J, additional, Bestwick, JP, additional, Meier, U-C, additional, Marta, M, additional, Costa, G Dalla, additional, Runia, T, additional, Evdoshenko, E, additional, Lazareva, N, additional, Thouvenot, E, additional, Iaffaldano, P, additional, Direnzo, V, additional, Khademi, M, additional, Piehl, F, additional, Comabella, M, additional, Sombekke, M, additional, Killestein, J, additional, Hegen, H, additional, Rauch, S, additional, D’Alfonso, S, additional, Alvarez-Cermeño, JC, additional, Kleinová, P, additional, Horáková, D, additional, Roesler, R, additional, Lauda, F, additional, Llufriu, S, additional, Avsar, T, additional, Uygunoglu, U, additional, Altintas, A, additional, Saip, S, additional, Menge, T, additional, Rajda, C, additional, Bergamaschi, R, additional, Moll, N, additional, Khalil, M, additional, Marignier, R, additional, Dujmovic, I, additional, Larsson, H, additional, Malmestrom, C, additional, Scarpini, E, additional, Fenoglio, C, additional, Wergeland, S, additional, Laroni, A, additional, Annibali, V, additional, Romano, S, additional, Martínez, AD, additional, Carra, A, additional, Salvetti, M, additional, Uccelli, A, additional, Torkildsen, Ø, additional, Myhr, KM, additional, Galimberti, D, additional, Rejdak, K, additional, Lycke, J, additional, Frederiksen, JL, additional, Drulovic, J, additional, Confavreux, C, additional, Brassat, D, additional, Enzinger, C, additional, Fuchs, S, additional, Bosca, I, additional, Pelletier, J, additional, Picard, C, additional, Colombo, E, additional, Franciotta, D, additional, Derfuss, T, additional, Lindberg, RLP, additional, Yaldizli, Ö, additional, Vécsei, L, additional, Kieseier, BC, additional, Hartung, HP, additional, Villoslada, P, additional, Siva, A, additional, Saiz, A, additional, Tumani, H, additional, Havrdová, E, additional, Villar, LM, additional, Leone, M, additional, Barizzone, N, additional, Deisenhammer, F, additional, Teunissen, C, additional, Montalban, X, additional, Tintoré, M, additional, Olsson, T, additional, Trojano, M, additional, Lehmann, S, additional, Castelnovo, G, additional, Lapin, S, additional, Hintzen, R, additional, Kappos, L, additional, Furlan, R, additional, Martinelli, V, additional, Comi, G, additional, Ramagopalan, SV, additional, and Giovannoni, G, additional

Published
2015
Full Text
View/download PDF

5. Significant clinical worsening after natalizumab withdrawal: Predictive factors

Author

Vidal-Jordana, A, primary, Tintoré, M, additional, Tur, C, additional, Pérez-Miralles, F, additional, Auger, C, additional, Río, J, additional, Nos, C, additional, Arrambide, G, additional, Comabella, M, additional, Galán, I, additional, Castilló, J, additional, Sastre-Garriga, J, additional, Rovira, A, additional, and Montalban, X, additional

Published
2014
Full Text
View/download PDF

8. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development

Author

Hegen, H, primary, Millonig, A, additional, Bertolotto, A, additional, Comabella, M, additional, Giovanonni, G, additional, Guger, M, additional, Hoelzl, M, additional, Khalil, M, additional, Killestein, J, additional, Lindberg, R, additional, Malucchi, S, additional, Mehling, M, additional, Montalban, X, additional, Polman, CH, additional, Rudzki, D, additional, Schautzer, F, additional, Sellebjerg, F, additional, Sørensen, PS, additional, and Deisenhammer, F, additional

Published
2013
Full Text
View/download PDF

9. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration

Author

Kearney, H, primary, Rocca, MA, additional, Valsasina, P, additional, Balk, L, additional, Sastre-Garriga, J, additional, Reinhardt, J, additional, Ruggieri, S, additional, Rovira, A, additional, Stippich, C, additional, Kappos, L, additional, Sprenger, T, additional, Tortorella, P, additional, Rovaris, M, additional, Gasperini, C, additional, Montalban, X, additional, Geurts, JJG, additional, Polman, CH, additional, Barkhof, F, additional, Filippi, M, additional, Altmann, DR, additional, Ciccarelli, O, additional, Miller, DH, additional, and Chard, DT, additional

Published
2013
Full Text
View/download PDF

10. Clinical impact of early brain atrophy in clinically isolated syndromes

Author

Pérez-Miralles, F, primary, Sastre-Garriga, J, additional, Tintoré, M, additional, Arrambide, G, additional, Nos, C, additional, Perkal, H, additional, Río, J, additional, Edo, MC, additional, Horga, A, additional, Castilló, J, additional, Auger, C, additional, Huerga, E, additional, Rovira, A, additional, and Montalban, X, additional

Published
2013
Full Text
View/download PDF

11. Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study.

Author

Tillema, J. M., Hulst, H. E., Rocca, M. A., Vrenken, H., Steenwijk, M. D., Damjanovic, D., Enzinger, C., Ropele, S., Tedeschi, G., Gallo, A., Ciccarelli, O., Rovira, A., Montalban, X., de Stefano, N., Stromillo, M. L., Filippi, M., and Barkhof, F.

Subjects
MULTIPLE sclerosis, COGNITION disorders, COGNITION, BRAIN imaging, NEUROPSYCHOLOGICAL tests
Abstract

Objectives: The objectives of this paper are to compare in a multicenter setting patterns of regional cortical thickness in patients with relapsing–remitting multiple sclerosis (RRMS) and cognitive impairment (CI) and those cognitively preserved (CP), and explore the relationship between cortical thinning and cognitive performance. Methods: T1-weighted isotropic brain scans were collected at 3T from seven European centers in 60 RRMS patients and 65 healthy controls (HCs). Patients underwent clinical and neuropsychological examinations. Cortical thickness (CTh) measures were calculated using FreeSurfer (failing in four) and both lobar and vertex-based general linear model (GLM) analyses were compared between study groups. Results: Twenty (36%) MS patients were classified as CI. Mean global CTh was smaller in RRMS patients compared to HCs (left 2.43 vs. 2.53 mm, right 2.44 vs. 2.54 mm, p < 0.001). Multivariate GLM regional analysis showed significantly more temporal thinning in CI compared to CP patients. Verbal memory scores correlated to regional cortical thinning in the insula whereas visual memory scores correlated to parietal thinning. Conclusions: This multicenter study showed mild global cortical thinning in RRMS. The extent of thinning is less pronounced than previously reported. Only subtle regional differences between CI and CP patients were observed, some of which related to specific cognitive domains. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

15. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis

Author

Cantó, E, primary, Reverter, F, additional, Morcillo-Suárez, C, additional, Matesanz, F, additional, Fernández, O, additional, Izquierdo, G, additional, Vandenbroeck, K, additional, Rodríguez-Antigüedad, A, additional, Urcelay, E, additional, Arroyo, R, additional, Otaegui, D, additional, Olascoaga, J, additional, Saiz, A, additional, Navarro, A, additional, Sanchez, A, additional, Domínguez, C, additional, Caminero, A, additional, Horga, A, additional, Tintoré, M, additional, Montalban, X, additional, and Comabella, M, additional

Published
2011
Full Text
View/download PDF

16. Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis

Author

Freedman, MS, primary, Metzig, C, additional, Kappos, L, additional, Polman, CH, additional, Edan, G, additional, Hartung, H-P, additional, Miller, DH, additional, Montalban, X, additional, Yarden, J, additional, Spector, L, additional, Fire, E, additional, Dotan, N, additional, Schwenke, S, additional, Lanius, V, additional, Sandbrink, R, additional, and Pohl, C, additional

Published
2011
Full Text
View/download PDF

21. Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study

Author

Mesaros, S., primary, Rocca, MA, additional, Sormani, MP, additional, Valsasina, P., additional, Markowitz, C., additional, De Stefano, N., additional, Montalban, X., additional, Barkhof, F., additional, Ranjeva, JP, additional, Sailer, M., additional, Kappos, L., additional, Comi, G., additional, and Filippi, M., additional

Published
2010
Full Text
View/download PDF

23. Primary progressive multiple sclerosis diagnostic criteria: a reappraisal

Author

Montalban, X., primary, Sastre-Garriga, J., additional, Filippi, M., additional, Khaleeli, Z., additional, Téllez, N., additional, Vellinga, MM, additional, Tur, C., additional, Brochet, B., additional, Barkhof, F., additional, Rovaris, M., additional, Miller, DH, additional, Polman, CH, additional, Rovira, A., additional, and Thompson, AJ, additional

Published
2009
Full Text
View/download PDF

26. Differential diagnosis of suspected multiple sclerosis: a consensus approach

Author

Miller, DH, primary, Weinshenker, BG, additional, Filippi, M, additional, Banwell, BL, additional, Cohen, JA, additional, Freedman, MS, additional, Galetta, SL, additional, Hutchinson, M, additional, Johnson, RT, additional, Kappos, L, additional, Kira, J, additional, Lublin, FD, additional, McFarland, HF, additional, Montalban, X, additional, Panitch, H, additional, Richert, JR, additional, Reingold, SC, additional, and Polman, CH, additional

Published
2008
Full Text
View/download PDF

29. Brain atrophy in natalizumab-treated patients: A 3-year follow-up.

Author

Sastre-Garriga, J, Tur, C, Pareto, D, Vidal-Jordana, A, Auger, C, Río, J, Huerga, E, Tintoré, M, Rovira, A, and Montalban, X

Subjects
BRAIN physiology, NATALIZUMAB, MAGNETIC resonance imaging, MULTIVARIATE analysis, INFLAMMATION
Abstract

The article presents a study which investigates the volume dynamics of the brain in patients who are treated with natalizumab after the initiation of therapy. The study uses the magnetic resonance imaging scans and multivariate models for the investigation of the link between the baseline inflammation and the changes to the volume and disability of the brain. Results show that the measures of the volume of the brain is affected by the baseline inflammation after the initiation of natalizumab.

Published
2015
Full Text
View/download PDF

30. Significant clinical worsening after natalizumab withdrawal: Predictive factors.

Author

Vidal-Jordana, A, Tintoré, M, Tur, C, Pérez-Miralles, F, Auger, C, Río, J, Nos, C, Arrambide, G, Comabella, M, Galán, I, Castilló, J, Sastre-Garriga, J, Rovira, A, and Montalban, X

Subjects
DRUG withdrawal symptoms, MAGNETIC resonance imaging, MULTIPLE sclerosis, NATALIZUMAB, PREDICTIVE control systems
Abstract

We aimed to single out multiple sclerosis (MS) cases with poor outcome after natalizumab withdrawal and to identify predictive variables. We ascertained 47 withdrawals, and compared their pre- and post-natalizumab periods. We objectively defined significant clinical worsening after natalizumab withdrawal as a 2-step increase in Expanded Disability Status Scale (EDSS). We performed regression models. As a group, post-natalizumab annualized relapse rate (ARR) was lower in the post-natalizumab period, and there were no differences in the mean number of gadolinium (Gd)-enhancing lesions between pre- and post-natalizumab magnetic resonance imaging (MRI). Corticosteroid treatment did not change the outcomes. Eight patients (19%) presented significant clinical worsening after natalizumab withdrawal, which was predicted by a higher baseline EDSS and a 1-step EDSS increase while on natalizumab. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

37. Can the Expanded Disability Status Scale be assessed by telephone?

Author

Lechner-Scott, J, primary, Kappos, L, additional, Hofman, M, additional, Polman, C H, additional, Ronner, H, additional, Montalban, X, additional, Tintore, M, additional, Frontoni, M, additional, Buttinelli, C, additional, Amato, M P, additional, Bartolozzi, M L, additional, Versavel, M, additional, Dahlke, F, additional, Kapp, J-F, additional, and Gibberd, R, additional

Published
2003
Full Text
View/download PDF

44. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.

Author

Izquierdo, G, O’Connor, P, Montalban, X, von Rosenstiel, P, Cremer, M, de Vera, A, Sfikas, N, Francis, G, Radue, EW, and Kappos, L

Subjects
FINGOLIMOD, MULTIPLE sclerosis, PLACEBOS, PROGNOSIS, MAGNETIC resonance imaging
Abstract

We present here results at 60 months (M), from the extension component of a phase 2, randomized, placebo-controlled, double-blind, six-month study evaluating oral fingolimod (1.25 mg or 5 mg daily) in relapsing multiple sclerosis. Placebo patients from the core study were re-randomized to fingolimod 1.25 mg or 5 mg in the extension. All patients received 1.25 mg fingolimod after the M24 visit. A total of 140/281 (49.8%) patients completed M60. Fingolimod treatment was associated with a low annualized relapse rate (0.2 relapses/ year), low MRI activity, and a modest rate of disability progression in those treated for five years. No new safety issues were reported. [ABSTRACT FROM PUBLISHER]

Published
2014
Full Text
View/download PDF

45. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.

Author

Hegen, H, Millonig, A, Bertolotto, A, Comabella, M, Giovanonni, G, Guger, M, Hoelzl, M, Khalil, M, Killestein, J, Lindberg, R, Malucchi, S, Mehling, M, Montalban, X, Polman, CH, Rudzki, D, Schautzer, F, Sellebjerg, F, Sørensen, PS, and Deisenhammer, F

Subjects
IMMUNOGLOBULINS, INTERFERONS, MULTIPLE sclerosis, TITERS, DRUG resistance, BIOMARKERS, PATIENTS
Abstract

The article presents a study of the potential of early binding antibody (BAb) titers or different interferon-beta (IFN-b) biomarkers to predict neutralizing antibodies (NAb). The study included patients with multiple sclerosis (MS) or clinically isolated syndrome (CIS) that receive de novo IFN-b treatment. Results showed that BAb titers reliably predict Nabs, with CXCL-10 as a potential sensitive biomarker for IFN-b response and abrogation by anti-IFN-b antibodies.

Published
2014
Full Text
View/download PDF

46. Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration.

Author

Kearney, H, Rocca, MA, Valsasina, P, Balk, L, Sastre-Garriga, J, Reinhardt, J, Ruggieri, S, Rovira, A, Stippich, C, Kappos, L, Sprenger, T, Tortorella, P, Rovaris, M, Gasperini, C, Montalban, X, Geurts, JJG, Polman, CH, Barkhof, F, Filippi, M, and Altmann, DR

Subjects
MULTIPLE sclerosis, MAGNETIC resonance imaging, CENTRAL nervous system, LONG-term care of people with disabilities, SPINAL cord
Abstract

The article discusses a study which was aimed to investigate the relationship of spinal cord and brain atrophy, and brain lesion load, with long-term physical disability in a large group of people with multiple scelrosis (MS). The study concluded that long-term physical disability was independently linked with atrophy of the spinal cord and brain T2 lesion load, and less consistently, with brain grey matter atrophy.

Published
2014
Full Text
View/download PDF

47. Scoring treatment response in patients with relapsing multiple sclerosis.

Author

Sormani, MP, Rio, J, Tintorè, M, Signori, A, Li, D, Cornelisse, P, Stubinski, B, Stromillo, ML, Montalban, X, and De Stefano, N

Subjects
MULTIPLE sclerosis, DIAGNOSTIC imaging, MAGNETIC resonance imaging, THERAPEUTIC use of interferons, INTERFERON beta-1a, MEDICAL decision making, PATIENTS
Abstract

The article presents a study on the assessing treatment response of patients with multiple sclerosis (MS) through clinical and magnetic resonance imaging (MRI). It mentions that two datasets of relapsing-remitting multiple sclerosis (RRMS) patients were used, in which one set had 373 RRMS patients treated with subcutaneous interferon beta-1a and the other one with 222 patients treated with different interferons. It adds that the result of the study can help in the decision making of clinicians.

Published
2013
Full Text
View/download PDF

48. SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis.

Author

Malhotra, S, Castilló, J, Bustamante, MF, Vidal-Jordana, A, Castro, Z, Montalban, X, and Comabella, M

Subjects
LECTINS, SIALIC acids, MONOCYTES, MULTIPLE sclerosis, FLOW cytometry, PATIENTS
Abstract

The article presents a study which investigates the role of two sialic acid binding immunoglobulin-like lectin (Siglec) family members SIGLECI and SIGLEC7 in circulating monocytes of patients with multiple sclerosis (MS). The study uses flow cytometry to determine the expression of SIGLECI and SIGLEC7. Results show that SIGLECI expression was significantly increased in MS patients compared with controlled group, while SIGLEC7 expression was up-regulated in blood monocytes.

Published
2013
Full Text
View/download PDF

49. Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain.

Author

Otero-Romero, S, Roura, P, Solà, J, Altimiras, J, Sastre-Garriga, J, Nos, C, Vaqué, J, Montalban, X, and Bufill, E

Subjects
MULTIPLE sclerosis, DISEASE prevalence, CROSS-sectional method
Abstract

The prevalence of multiple sclerosis in the south of Europe seems to be higher than previously considered. This study aimed to probe a possible increase in the prevalence of multiple sclerosis (MS) in Osona over the past 17 years. This was a cross-sectional study including MS-confirmed cases from several sources of information. Crude and adjusted prevalence rates were obtained. One hundred and twenty patients fulfilled the study criteria. The crude prevalence of MS was 79.9 (95% CI: 66.3–95.6) per 100,000 inhabitants and 91.2 (95% CI: 75.5–109.2) per 100,000 among Spanish born individuals. The prevalence of multiple sclerosis cases in Osona has increased over the past 17 years to being one of the highest reported in Spain. [ABSTRACT FROM PUBLISHER]

Published
2013
Full Text
View/download PDF

50. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis.

Author

Cantó, E, Reverter, F, Morcillo-Suárez, C, Matesanz, F, Fernández, O, Izquierdo, G, Vandenbroeck, K, Rodríguez-Antigüedad, A, Urcelay, E, Arroyo, R, Otaegui, D, Olascoaga, J, Saiz, A, Navarro, A, Sanchez, A, Domínguez, C, Caminero, A, Horga, A, Tintoré, M, and Montalban, X

Subjects
CHITINASE, GLYCOSIDASES, BLOOD plasma, MULTIPLE sclerosis, ENZYME-linked immunosorbent assay, PATIENTS
Abstract

The article presents a study which examines the role of plasma chitinase 3-like 1 (CHI3LI) in patients with multiple sclerosis (MS) clinican course and the activity of disease. The study used enzyme-linked immunosorbent assay (ELISA) to determine the levels of plasma CHI3L1. Results showed that plasma CHI3L1 levels were importantly increased in patients with progressive for of MS compared with relapsing-remitting (RRMS) patients.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results